Rebound of antitopoisomerase I antibody titres after plasma exchange Sir: Serum levels of a specific antibody induce a negative feedback on the synthesis of antibody of the same specificity.' 2 If this feedback inhibition of antibody synthesis is reduced by diminishing the concentration of antibody in the circulation by plasma exchange (PE) an enhancement of antibody synthesis, also termed 'antibody rebound', occurs. This rebound phenomenon has been shown to occur, among others, in autoimmune mediated diseases such as systemic lupus erythematosus.3 Plasma exchange, alone or combined with immunosuppressive therapy, has been used in the treatment of systemic sclerosis,' though its effectiveness in this disorder remains questionable.7 Changes in autoantibody concentrations during PE treatment of patients with scleroderma have been used to monitor the efficacy of PE. . He was treated with prednisolone and cyclophosphamide and is currently well.
The temporal relation between the angioplasty and the development of polyarteritis nodosa in this case strongly suggests a link. Vascular damage certainly occurs during angioplasty and up to 2% of all femoral angioplasties require surgical intervention.4 Thus several mechanisms might have stimulated the immune response, leading to the development of vasculitis. The simplest of these involves the exposure of previously hidden epitopes to which the patient was not tolerant. Besides simple traumatic damage to the vascular endothelium, however, angioplasty may also render the area temporarily ischaemic. In coronary angioplasty this is known to result in the generation of superoxides.5 In this case it is interesting to note that the left calf was the worst affected area. Could ischaemically generated superoxides have altered endothelial constituents, rendering them antigenic? This is the first reported case of vasculitis after angioplasty. With the increasing use of such techniques, more can presumably be expected. The procedure provides an interesting opportunity for further research. Buerger's disease and antiphospholipid antibodies in pregnancy Sir: Buerger's disease is a vasculitis of unknown cause, in which several factors have been implicated, one of the most important of which is smoking.' We present a case in which Buerger's disease was associated with a primary antiphospholipid syndrome in a pregnant woman.
A patient aged 38 was sent to our centre in her 32nd week of gestation with a suspected diagnosis of intrauterine growth retardation. Her obstetric history included two intrauterine fetal deaths at 30 and 32 weeks, and between them a male child born alive at term but who was small for the gestational age. The patient had smoked more than 30 cigarettes daily for the previous three years and had had a history of Raynaud's disease in the fingers and toes for nine years, with distal necrosis of the middle finger of the right hand. On examination, the absence of left radial and pedal pulse and signs of necrosis of the middle finger of the right hand were noteworthy. Uterine height was 22 cm, which clearly was low for the gestational age. Blood analysis showed persistent thrombocytopenia, with a platelet count between 100 and 140X i09/1. 
